The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

First, let's back up a bit and take a look at the Moderna story, from the glory days of a few years ago to its troubles today ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...